Discover what's possible with your RYBREVANT FASPRO™–based or RYBREVANT®-based treatment:
Live longer
People taking RYBREVANT® + LAZCLUZE® (lazertinib) lived longer than people taking Tagrisso® (osimertinib) alone†
Have more time without cancer getting worse
RYBREVANT® + LAZCLUZE® helped keep cancer from growing or spreading better than Tagrisso® (osimertinib) alone‡
Get chemo-free care
RYBREVANT® + LAZCLUZE® is a chemo-free combination treatment
Whether you receive RYBREVANT FASPRO™ injections or RYBREVANT® infusions, both ways are similarly helpful in treating your cancer.
RYBREVANT FASPRO™ is not recommended for people who have had allergic reactions to hyaluronidase or any of its ingredients. RYBREVANT FASPRO™ or RYBREVANT® + LAZCLUZE® may cause serious side effects, such as allergic and injection-related or infusion-related reactions, including life-threatening (anaphylaxis) allergic reactions, lung, blood clot, skin, liver, and eye problems. Learn more about possible side effects here.
Where did these results come from?
RYBREVANT® + LAZCLUZE® was compared with Tagrisso® (osimertinib) in a clinical trial. A group of 858 people received either RYBREVANT® + LAZCLUZE® or Tagrisso® (osimertinib) as their first treatment for advanced or metastatic EGFR-mutant NSCLC with exon 19 deletion or exon 21 L858R substitution mutations. The main goal of the clinical trial was to measure how long people were on treatment before their cancer started growing or spreading. A secondary goal of the clinical trial was to measure how long people in the study lived.
*Exon 19 deletion or exon 21 L858R substitution mutations.
†In this trial, median overall survival for RYBREVANT® + LAZCLUZE® had not yet been reached at the time of analysis, which means more than half of those patients were alive when the data were reviewed. On the other hand, half of the people taking Tagrisso® (osimertinib) were no longer alive at 36.7 months.
‡At 23.7 months, half of the people taking RYBREVANT® + LAZCLUZE® lived without their cancer growing or spreading, compared with 16.6 months with Tagrisso® (osimertinib) alone.
Third-party trademark used herein is a trademark of its respective owner.
EGFR+, mutated epidermal growth factor receptor; NSCLC, non–small cell lung cancer.
